As an M.D. with a Ph.D. in pharmacology, coupled with 14 years of industry experience, Paul is uniquely qualified to translate science into effective clinical development and regulatory programs. At his current position as the Chief Medical Officer at Profibrix, a small European biotech company that develops innovative products for hemostasis, Dr. Frohna designs the translational medicine programs for recombinant human fibrinogen (and variants) for severe bleeding and regenerative medicine indications.